1Y Target$45.72Near-term target
5Y Target$68.12Compound horizon
10Y Target$177.27Long-dated conviction
FCF-$533mTTM · 03/26FFCF is negative (-$533m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+7.2%TTM YoYBRevenue +7.2% — at or above S&P median
D/E0.31totalB+D/E 0.31 — healthy leverage, well below danger zone · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S4.6xBP/S 4.6x — in line with software/tech peers
PEG—proxy—PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Media · market cap $4.9b. Down 64% from 52-week high of $94.62 — deep drawdown territory.
Moat
Net margin 103% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma.
Risk
Free cash flow is negative (-$533m) — capital raises or debt issuance likely required; dilution / leverage risk. Down 64% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. ROE -31% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $45.72 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $68.12 — requires the platform / technology to reach commercial scale. 10 yr $177.27 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.